← Back to Clinical Trials
Recruiting NCT06657898

NCT06657898 Complicated Pneumonia (CP) in Children in South-East Europe

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06657898
Status Recruiting
Phase
Sponsor Aleksandar Sovtic
Condition Pneumonia, Necrotizing
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-05-27
Primary Completion 2025-06-01

Eligibility & Interventions

Sex All sexes
Min Age 1 Month
Max Age 18 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-05-27 with a primary completion date of 2025-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This retrospective observational study aims to evaluate clinical course of complicated community acquired pneumonia in children, particularly focusing on necrotizing pneumonia cases, as well as determination of etiological agents (viruses and bacteria) and its association to severity and outcomes of the disease. Furthermore, therapeutic approach, complications, short-term and long-term outcomes and the prevention of the disease are to be assessed. The study will encompass data from pediatric centers in the South-East Europe willing to participate in the study, encompassing ten-year period of time.

Eligibility Criteria

Inclusion Criteria * Children aged 1 month to 18 years of age * Children diagnosed with complicated community acquired pneumonia (pneumonia with parapneumonic effusion, necrotizing pneumonia and lung abscess) * Children who were hospitalized from January 1st 2014 to April 30th 2024 and required at least 24 hours of hospital stay Exclusion Criteria * Children with increased risk for severe lung infections (cystic fibrosis, primary ciliary dyskinesia, immunodeficiencies, congenital lung abnormalities, neurological conditions, chemotherapy) * Children with hospital-acquired pneumonia

Contact & Investigator

Central Contact

Aleksandar Sovtic, M.D. Ph.D

✉ aleksandar.sovtic@imd.org.rs

📞 +381113108158

Frequently Asked Questions

Who can join the NCT06657898 clinical trial?

This trial is open to participants of all sexes, aged 1 Month or older, up to 18 Years, studying Pneumonia, Necrotizing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06657898 currently recruiting?

Yes, NCT06657898 is actively recruiting participants. Contact the research team at aleksandar.sovtic@imd.org.rs for enrollment information.

Where is the NCT06657898 trial being conducted?

This trial is being conducted at Belgrade, Serbia.

Who is sponsoring the NCT06657898 clinical trial?

NCT06657898 is sponsored by Aleksandar Sovtic. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology